RCT-2100 is under development for the treatment of cystic fibrosis (CF). The therapeutic candidate is an mRNA, encoding cystic fibrosis transmembrane conductance regulator (CFTR). It is administered ...

Galicaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

The U.S. military flew six of the injured to Phoenix for treatment on Saturday because Hawaii’s lone burn unit doesn’t have ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectivelyMore than 3,500 ...

Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Arcturus Therapeutics (ARCT – Research Report). The associated price ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Preview report featuring updated forecasts for the biopharma market for 2025.

New breakthroughs in gene editing mean that cures for genetic diseases such as cystic fibrosis could be developed in the near ...

The rules around donation are pretty clear. In cases of egg donation, the woman who carries and gives birth to the child is ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...